SCHEMBL20135211

SCHEMBL20135211

Cc1ccc(C(=O)c2cnn(C3CCN(C(=O)c4ccc([C@@]5(C)NC(=O)NC5=O)cc4)CC3)c2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
MMP2 P08253 1/20 0.37
MMP9 P14780 1/20 0.37
CRBN Q96SW2 2/20 0.37
HSD11B1 P28845 1/20 0.36
MGLL Q99685 1/20 0.36
ACACB O00763 1/20 0.36
ACACA Q13085 1/20 0.36
PKM P14618 1/20 0.36
PAK1 Q13153 1/20 0.36
GABRD O14764 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA2 P47869 1/20 0.35
GABRB2 P47870 1/20 0.35
GABRA4 P48169 1/20 0.35
ALDH1A1 P00352 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135214 1.00 KMT2A (0.39) KMT2AMEN1MMP2MMP9CRBN
SCHEMBL20135213 0.91 MEN1 (0.39) KMT2AMEN1MMP2MMP9CRBN
SCHEMBL20134876 0.80 MEN1 (0.65) KMT2AMEN1HSD11B1MGLLALDH1A1
SCHEMBL20134877 0.80 MEN1 (0.65) KMT2AMEN1HSD11B1MGLLALDH1A1
SCHEMBL20134802 0.79 KDM5A (0.39) KMT2AMEN1MMP2MMP9CRBN
SCHEMBL20134801 0.79 KDM5A (0.39) KMT2AMEN1MMP2MMP9CRBN
SCHEMBL20134790 0.78 TLR8 (0.43) KMT2AMEN1CRBNHSD11B1ACACB
SCHEMBL20134970 0.78 MGLL (0.39) KMT2AMEN1MMP2MMP9CRBN
SCHEMBL20134973 0.78 MGLL (0.39) KMT2AMEN1MMP2MMP9CRBN
SCHEMBL20134793 0.78 TLR8 (0.43) KMT2AMEN1CRBNHSD11B1ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 KMT2A 2568/4885MEN1 3735/4885MMP2 4/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 KMT2A 2539/4885MEN1 2913/4885MMP2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.